沿阿尔茨海默氏病连续线的区域大脑血流和大脑功能脱
Jixuan Li1, Qingze Zeng1, Xiao Luo1
1Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Journal of Alzheimer's disease : JAD
|July 24, 2023
概括
阿尔茨海默氏病的病理学早期破坏神经血管合,甚至在认知能力下降之前. 这种CBF/ReHo比率可能有助于检测早期的AD变化,独立于小血管疾病.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 与神经血管合障碍有关.
- 在AD连续体中神经血管合的早期变化尚未得到充分理解.
研究的目的:
- 调查认知正常和轻度认知障碍老年人的早期神经血管合障碍.
- 检查神经血管合,认知和AD病理之间的关联.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划的数据.
- 使用大脑血流 (CBF) /区域同质性 (ReHo) 比率评估神经血管合.
- 与AD生物标志物,认知和小血管疾病 (SVD) 负担相关的CBF/ReHo比率.
主要成果:
- 粉样β阳性个体显示CBF/ReHo比率降低,特别是在部区域.
- 较低的CBF/ReHo比率与较差的认知得分和较高的AD病理相关.
- 在CBF/ReHo比率和SVD负担之间没有发现关联.
结论:
- 阿尔茨海默病的病理学是神经血管合障碍的一个关键因素,独立于SVD.
- CBF/ReHo比率显示,它有可能成为AD中神经血管合异常的早期诊断标志物.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.5K
06:34Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
Published on: June 2, 2023
1.2K
相关概念视频
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219